Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
6 FDA Decisions To Watch in Q2 2026
The second quarter of 2026 is anticipated to be a busy one for the FDA, with several significant decisions on new therapies, including a closely watched obesity drug from Eli Lilly. Other key decisions involve Biogen’s high-dose Spinraza for SMA, Replimune’s RP1 for advanced melanoma, Axsome Therapeutics’ AXS-05 for Alzheimer’s agitation, Biogen and Eisai’s subcutaneous Leqembi, and AstraZeneca’s baxdrostat for hypertension. These regulatory verdicts could significantly impact treatment landscapes in various disease areas and intensify market competition.